Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0215)
Name
Norcantharidin
Synonyms
Norcantharidin; 5442-12-6; Endothall anhydride; 29745-04-8; Norcantharadine; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; 3,6-Endoxohexahydrophthalic anhydride; 4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; (+/-)-Norcantharidin; Isocantharidin; (+/-)-NCTD; NCTD; exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; DEMETHYL-CANTHARIDIN; NSC-14003; NSC-59023; 3, hexahydro-; NSC 14003; Norcantharidin, solid; Spectrum_001667; 3,6-Endooxyphthalic anhydride, hexahydro-; SpecPlus_000904; Phthalic anhydride, hexahydro-3,6-endoxo-; 4,3-dione, hexahydro-; Spectrum2_001683; Spectrum3_001634; Spectrum4_000601; Spectrum5_001514; CHEMBL8327; Lopac0_000830; BSPBio_003327; KBioGR_001122; KBioSS_002147; Phthalic anhydride,6-endoxo-; MLS002153470; DivK1c_007000; SCHEMBL177729; SPECTRUM1504153; SPBio_001606; YSCH0101; 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione; KBio1_001944; KBio2_002147; KBio2_004715; KBio2_007283; KBio3_002547; DTXSID30884158; JAABVEXCGCXWRR-UHFFFAOYSA-N; HMS3262F21; HMS3370H07; BCP09826; BCP25426; HY-N0585; NSC14003; NSC59023; Tox21_500830; WLN: T C555 A AO DVOVTJ; CCG-39454; MFCD00213361; NSC148536; s3759; STK424286; AKOS003267901; FS-4623; LP00830; NSC-148536; SDCCGSBI-0050807.P003; NCGC00015756-03; NCGC00015756-04; NCGC00015756-05; NCGC00015756-06; NCGC00015756-07; NCGC00015756-08; NCGC00015756-09; NCGC00015756-14; NCGC00094161-01; NCGC00094161-02; NCGC00094161-03; NCGC00094161-04; NCGC00094161-05; NCGC00094161-06; NCGC00261515-01; NCI60_001019; SMR000326693; CS-0009119; EU-0100830; FT-0614776; FT-0621477; FT-0626378; hexahydro-4,7-epoxy-2-benzofuran-1,3-dione; N 8784; 3,6-Endoxohexahydrophthalic anhydride, exo isomer; SR-01000076037; SR-01000076037-1; BRD-A66914119-001-04-0; Q15425762; 4,10-Dioxa-tricyclo[5.2.1.02,6]decane-3,5-dione; 3-(5'-(4-(diphenylamino)phenyl)-[2,2'-bithiophen]-5-yl)cyclohex-2-enone; EXO-7-OXA-BICYCLO(2.2.1)-HEPTANE-2,3-DICARBOXYLIC ANHYDRIDE; Exo-cis-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; Endothall anhydride; 4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; 51154-98-4; TIMTEC-BB SBB005955;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-;4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione

    Click to Show/Hide
Structure
Formula
C8H8O4
IUPAC Name
4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
Canonical SMILES
C1CC2C3C(C1O2)C(=O)OC3=O
InChI
InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2
InChIKey
JAABVEXCGCXWRR-UHFFFAOYSA-N
PubChem CID
93004
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Athymic nu/nu female mice aged 6-8 weeks (n = 9; mean weight, 20.21 ± 1.54 g) were purchased from the specific pathogen SPF (Beijing) Lab Animals Technology Co. Ltd. Mice were housed in a temperature- and humidity-controlled environment (20-24 , 45-55% humidity), with free access to food and water and in groups of three. All procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC ID: 17-3256) at Nantong University and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

    Click to Show/Hide
Response regulation Nuclear factor erythroid 2-related factor 2 (NRF2), heme oxygenase 1 (HO-1), glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (xCT) expression levels were significantly decreased following norcantharidin (NCTD) treatment. Collectively, NCTD may represent a potent anticancer agent in ovarian cancer cells, and NCTD-induced ferroptotic cell death may be achieved by inhibiting the NRF2/HO-1/GPX4/xCT axis.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Athymic nu/nu female mice aged 6-8 weeks (n = 9; mean weight, 20.21 ± 1.54 g) were purchased from the specific pathogen SPF (Beijing) Lab Animals Technology Co. Ltd. Mice were housed in a temperature- and humidity-controlled environment (20-24 , 45-55% humidity), with free access to food and water and in groups of three. All procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC ID: 17-3256) at Nantong University and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

    Click to Show/Hide
Response regulation Nuclear factor erythroid 2-related factor 2 (NRF2), heme oxygenase 1 (HO-1), glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (xCT) expression levels were significantly decreased following norcantharidin (NCTD) treatment. Collectively, NCTD may represent a potent anticancer agent in ovarian cancer cells, and NCTD-induced ferroptotic cell death may be achieved by inhibiting the NRF2/HO-1/GPX4/xCT axis.
Heme oxygenase 1 (HMOX1)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Athymic nu/nu female mice aged 6-8 weeks (n = 9; mean weight, 20.21 ± 1.54 g) were purchased from the specific pathogen SPF (Beijing) Lab Animals Technology Co. Ltd. Mice were housed in a temperature- and humidity-controlled environment (20-24 , 45-55% humidity), with free access to food and water and in groups of three. All procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC ID: 17-3256) at Nantong University and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

    Click to Show/Hide
Response regulation Nuclear factor erythroid 2-related factor 2 (NRF2), heme oxygenase 1 (HO-1), glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (xCT) expression levels were significantly decreased following norcantharidin (NCTD) treatment. Collectively, NCTD may represent a potent anticancer agent in ovarian cancer cells, and NCTD-induced ferroptotic cell death may be achieved by inhibiting the NRF2/ HO-1/GPX4/xCT axis.
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Athymic nu/nu female mice aged 6-8 weeks (n = 9; mean weight, 20.21 ± 1.54 g) were purchased from the specific pathogen SPF (Beijing) Lab Animals Technology Co. Ltd. Mice were housed in a temperature- and humidity-controlled environment (20-24 , 45-55% humidity), with free access to food and water and in groups of three. All procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC ID: 17-3256) at Nantong University and performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

    Click to Show/Hide
Response regulation Nuclear factor erythroid 2-related factor 2 (NRF2), heme oxygenase 1 (HO-1), glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (xCT) expression levels were significantly decreased following norcantharidin (NCTD) treatment. Collectively, NCTD may represent a potent anticancer agent in ovarian cancer cells, and NCTD-induced ferroptotic cell death may be achieved by inhibiting the NRF2/HO-1/GPX4/xCT axis.
References
Ref 1 Norcantharidin induces ferroptosis via the suppression of NRF2/HO-1 signaling in ovarian cancer cells. Oncol Lett. 2022 Aug 25;24(4):359. doi: 10.3892/ol.2022.13479. eCollection 2022 Oct.